Pediatrix Reports Earnings Growth Amid Declining Patient Volumes
On August 4, Pediatrix Medical Group (NYSE:MD) reported strong second-quarter results with adjusted earnings per share rising to $0.63 from $0.53 and net revenue increasing to $487.8 million year-over-year. The growth was primarily driven by higher reimbursement rates, improved cash collections, a shift toward commercial payors, and stock buybacks that reduced the number of shares outstanding. However, underlying volume trends were negative: hospital-based patient services fell 2.8%, office-based services dropped 1.2%, and neonatal intensive care unit days declined by 3.2%. These declines suggest a reduction in core service demand despite revenue growth. Additionally, costs rose faster than revenues in several areas, including higher salaries, malpractice expenses, and administrative costs. The company reaffirmed its full-year Adjusted EBITDA guidance of $280 million to $300 million but faces challenges with cash flow as cash on hand decreased from $375.2 million at the start of 2026 to $288.9 million by quarter-end.
Tickers: $MD
Topics: healthcare patient_volumes revenue_growth share_repurchase